Pediatrix Medical Group/$MD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pediatrix Medical Group
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Ticker
$MD
Sector
Primary listing
NYSE
Employees
4,120
Headquarters
Website
MD Metrics
BasicAdvanced
$1.5B
13.60
$1.29
1.26
-
Price and volume
Market cap
$1.5B
Beta
1.26
52-week high
$18.22
52-week low
$11.84
Average daily volume
699K
Financial strength
Current ratio
1.798
Quick ratio
1.744
Long term debt to equity
77.908
Total debt to equity
77.908
Interest coverage (TTM)
5.59%
Profitability
EBITDA (TTM)
236.725
Gross margin (TTM)
24.36%
Net profit margin (TTM)
5.66%
Operating margin (TTM)
10.97%
Effective tax rate (TTM)
22.39%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
6.50%
Return on equity (TTM)
14.27%
Valuation
Price to earnings (TTM)
13.602
Price to revenue (TTM)
0.763
Price to book
1.8
Price to tangible book (TTM)
-2.43
Price to free cash flow (TTM)
6.522
Free cash flow yield (TTM)
15.33%
Free cash flow per share (TTM)
2.698
Growth
Revenue change (TTM)
-3.08%
Earnings per share change (TTM)
-142.49%
3-year revenue growth (CAGR)
-0.32%
10-year revenue growth (CAGR)
-2.86%
3-year earnings per share growth (CAGR)
9.81%
10-year earnings per share growth (CAGR)
-9.17%
What the Analysts think about MD
Analyst ratings (Buy, Hold, Sell) for Pediatrix Medical Group stock.
Bulls say / Bears say
Pediatrix reported non-GAAP EPS of $0.53 in Q2 2025, topping the analyst consensus of $0.42 by 25.9%, and raised its full-year 2025 adjusted EBITDA guidance to $245–255 million from $220–240 million, reflecting strong execution and management confidence (Investing.com).
The company cut net debt from $515 million on September 30, 2024, to $386 million by year-end 2024, achieving net leverage of roughly 1.7 times while generating $135 million of operating cash flow in Q4 2024, improving balance sheet strength (GuruFocus).
Pediatrix repurchased $1.8 million of its own shares in H1 2025 and has $1.1 million remaining capacity under its $500 million buyback authorization, highlighting commitment to returning capital to shareholders (Nasdaq).
GAAP revenue for Q2 2025 declined by 7.0% year-over-year to $468.8 million, mainly due to practice sales, highlighting potential challenges in sustaining top-line growth through portfolio restructuring (Investing.com).
As of June 30, 2025, Pediatrix had total debt of $607.5 million, barely reduced from $615 million at year-end 2024, leaving the company vulnerable to interest-rate risk and liquidity pressures in a high-rate environment (Zacks).
Operating cash flow in H1 2025 was only $19.7 million, showing relatively weak cash generation compared to its debt load and capital spending needs, which could strain liquidity if not addressed (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MD Financial Performance
Revenues and expenses
MD Earnings Performance
Company profitability
MD News
AllArticlesVideos
Pediatrix Medical Group 2025 Third Quarter Conference Call/Webcast Scheduled for Monday, November 3, 2025
Business Wire5 days ago
Pediatrix Medical Group Announces $250 Million Share Repurchase Program
Business Wire2 months ago
Pediatrix Medical Group Reports Second Quarter Results
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pediatrix Medical Group stock?
Pediatrix Medical Group (MD) has a market cap of $1.5B as of October 26, 2025.
What is the P/E ratio for Pediatrix Medical Group stock?
The price to earnings (P/E) ratio for Pediatrix Medical Group (MD) stock is 13.6 as of October 26, 2025.
Does Pediatrix Medical Group stock pay dividends?
No, Pediatrix Medical Group (MD) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Pediatrix Medical Group dividend payment date?
Pediatrix Medical Group (MD) stock does not pay dividends to its shareholders.
What is the beta indicator for Pediatrix Medical Group?
Pediatrix Medical Group (MD) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.